Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.
María Dolores Corral SánchezVíctor Galán GómezAna Sastre UrgellesDiego Plaza López de SabandoPedro Rubio AparicioLeopoldo Martínez MartínezEduardo Alonso GamarraJosé Juan Pozo KreilingerRita María Regojo ZapataJuan Carlos López GutiérrezEugenia Antolín AlvaradoFelipe Gómez MartínAna María Sánchez TorresElena Marín ManzanoLuis González Del VallePérez-Martínez AntonioPublished in: Pediatric hematology and oncology (2021)
Infantile fibrosarcoma (IFS) is a rare pediatric tumor which often presents the ETV6-NTRK3 gene fusion. NTRK3 encodes the neurotrophin-3 growth factor receptor tyrosine kinase, a druggable therapeutic target. Selective tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib, have shown efficacy and safety in the treatment of IFS. We report a case of an abdominal IFS diagnosed in a newborn associated with an aortic aneurysm that was successfully treated with larotrectinib without relevant adverse effects.